Rigel Pharmaceuticals (RIGL) Projected to Post Quarterly Earnings on Thursday

Rigel Pharmaceuticals (NASDAQ:RIGL) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $0.73 per share and revenue of $61.8790 million for the quarter. Rigel Pharmaceuticals has set its FY 2025 guidance at EPS.Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its earnings results on Tuesday, August 5th. The biotechnology company reported $3.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.97 by $1.31. Rigel Pharmaceuticals had a return on equity of 438.89% and a net margin of 36.51%.The business had revenue of $101.69 million during the quarter, compared to analysts’ expectations of $64.58 million. On average, analysts expect Rigel Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Rigel Pharmaceuticals Trading Down 1.0%

Shares of RIGL opened at $29.40 on Thursday. Rigel Pharmaceuticals has a 1 year low of $13.57 and a 1 year high of $43.72. The company has a current ratio of 2.02, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46. The stock has a 50 day simple moving average of $33.32 and a 200-day simple moving average of $25.56. The stock has a market cap of $527.44 million, a PE ratio of 5.43 and a beta of 1.20.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on RIGL shares. Cantor Fitzgerald increased their target price on Rigel Pharmaceuticals from $23.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price target on shares of Rigel Pharmaceuticals in a report on Wednesday, October 8th. Zacks Research cut Rigel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $38.20.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc boosted its position in shares of Rigel Pharmaceuticals by 130.7% in the 2nd quarter. Legal & General Group Plc now owns 4,310 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 2,442 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in shares of Rigel Pharmaceuticals during the second quarter worth $178,000. AQR Capital Management LLC bought a new position in Rigel Pharmaceuticals during the first quarter worth about $191,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Rigel Pharmaceuticals by 14.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,366 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 1,464 shares in the last quarter. Finally, Man Group plc lifted its holdings in Rigel Pharmaceuticals by 14.6% during the second quarter. Man Group plc now owns 11,772 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 1,501 shares in the last quarter. 66.23% of the stock is owned by institutional investors and hedge funds.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.